Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
Follow-Up Questions
AWHL 주식의 가격 성능은 어떻습니까?
AWHL의 현재 가격은 $0.5299이며, 전 거래일에 decreased 0% 하였습니다.
Aspira Women's Health Inc의 주요 사업 주제나 업종은 무엇입니까?
Aspira Women's Health Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Aspira Women's Health Inc의 시가총액은 얼마입니까?
Aspira Women's Health Inc의 현재 시가총액은 $22.3M입니다
Aspira Women's Health Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Aspira Women's Health Inc에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 1명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다
